Societal CDMO, Inc.
Societal CDMO, Inc. (SCTL): 5 pipeline candidates · ~11 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
11.3 months
D/E 1.62 · 0% dilution
Lead: Approved
5 candidates
N/A
N/A
A transparent, data-derived signal for Societal CDMO, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$8.1M
Quarterly Burn
$5.8M
Runway
11.3 mo
Revenue
$27.7M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| donnatal | Approved |
| focalin xr | Approved |
| ritalin la | Approved |
| verapamil sr | Approved |
| verelan pm | Approved |
Frequently asked questions
How many drug candidates are in Societal CDMO, Inc.'s pipeline?
Societal CDMO, Inc. (SCTL) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Societal CDMO, Inc.'s lead drug candidate?
Societal CDMO, Inc.'s most advanced tracked candidate is donnatal (Approved) for Irritable bowel syndrome and acute enterocolitis.
What is Societal CDMO, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Societal CDMO, Inc. has approximately 11.3 months of cash runway.
Who is the CEO of Societal CDMO, Inc.?
David Enloe, Jr. is the chief executive officer of Societal CDMO, Inc. (SCTL).
Get the full picture on Societal CDMO, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.